Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus
Clinical narrative: glands swollen after 4 days; Fever 101; Headache; Joint pain; Swollen glands under left arm; Fatigue; swelling, pain, redness and itching at injection site; swelling, pain, redness and itching at injection site; swelling, pain, redness and itching at injection site; swelling, pain, redness and itching at injection site; have the booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Nov2021 13:15 (Lot number: FH8030) at the age of 53 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: FLU taken for immunisation, administration date 19Oct2021. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: EN6204; Anatomical site: Left arm; Administration time: 09:00), administration date: 25Mar2021, when the patient was 52 years old, for COVID-19 immunisation; Bnt162b2 (DOSE 2, SINGLE; Lot Number: EW0151; natomical site: Left leg; Administration time: 10:00), administration date: 15Apr2021, when the patient was 52 years old, for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 16Nov2021 13:15, outcome "unknown", described as "have the booster"; PYREXIA (non-serious) with onset 17Nov2021 12:00, outcome "recovered" (18Nov2021), described as "Fever 101"; HEADACHE (non-serious) with onset 17Nov2021 12:00, outcome "recovered" (18Nov2021), described as "Headache"; ARTHRALGIA (non-serious) with onset 17Nov2021 12:00, outcome "recovered" (18Nov2021), described as "Joint pain"; LYMPHADENOPATHY (non-serious) with onset 17Nov2021 12:00, outcome "recovered" (18Nov2021), described as "Swollen glands under left arm"; FATIGUE (non-serious) with onset 17Nov2021 12:00, outcome "recovered" (18Nov2021), described as "Fatigue"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE PRURITUS (non-serious) all with onset 17Nov2021 12:00, outcome "recovering" and all described as "swelling, pain, redness and itching at injection site"; VACCINATION SITE PAIN (non-serious) with onset 17Nov2021 12:00, outcome "not recovered", LYMPHADENOPATHY (non-serious) with onset 20Nov2021, outcome "unknown" and all described as "glands swollen after 4 days". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pyrexia, headache, arthralgia, lymphadenopathy, fatigue, vaccination site swelling, vaccination site pain, vaccination site erythema, vaccination site pruritus, lymphadenopathy.  Additional information: On 17Nov patient had lab test Body temperature showed 101. Pregnancy at time of Vaccination was no. Any other medications the patient received within 2 weeks of vaccination was no. Prior to vaccination, was the patient diagnosed with COVID-19 was no. Since the vaccination, has the patient been tested for COVID-19 was no.  Follow-up attempts are completed. No further information is expected.